Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: BRILINTA

Summary for Tradename: BRILINTA

Suppliers: see list2
patent expirations by year for

Clinical Trials for: BRILINTA

Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function
Status: Not yet recruiting Condition: ST-Segment Elevation Myocardial Infarction

Cangrelor Ticagrelor Transition Study
Status: Completed Condition: Coronary Artery Disease

High Ticagrelor Loading Dose in STEMI
Status: Completed Condition: Coronary Artery Disease

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Status: Recruiting Condition: Coronary Artery Disease

Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Status: Recruiting Condition: Coronary Artery Disease; Acute Coronary Syndrome

Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.
Status: Recruiting Condition: Platelet Reactivity

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
Status: Recruiting Condition: Acute Coronary Syndrome

Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.
Status: Completed Condition: Bioavailability Heathy Volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
Status: Recruiting Condition: Kidney Failure, Chronic

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Status: Recruiting Condition: Coronary Artery Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Lp
TABLET;ORAL022433Jul 20, 2011RXYes<disabled><disabled>
Astrazeneca Lp
TABLET;ORAL022433Jul 20, 2011RXYes6,251,910<disabled>Y<disabled>
Astrazeneca Lp
TABLET;ORAL022433Jul 20, 2011RXYes6,525,060<disabled>YY<disabled>
Astrazeneca Lp
TABLET;ORAL022433Jul 20, 2011RXYes7,250,419<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology